Osteopontin is a novel prognostic biomarker in early-stage non-small cell lung cancer after surgical resection

Journal of Cancer Research and Clinical Oncology

Volumn 141, Issue 8, 2015, Pages 1371-1378

  Yan, Ci Hui ^a   Lv, Mengguo ^a   Li, Hui ^a   Song, Xinmiao ^a   Yan, Fan ^a   Cao, Shui ^a   Ren, Xiubao ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Immunohistochemistry; NSCLC; Osteopontin; Prognosis

Indexed keywords

COMPLEMENTARY DNA; OSTEOPONTIN; TUMOR MARKERS, BIOLOGICAL;

ADULT; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; AGED; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; HUMANS; LUNG NEOPLASMS; LYMPH NODE EXCISION; METABOLISM; MIDDLE AGED; MORTALITY; NEOPLASM STAGING; PATHOLOGY; PNEUMONECTOMY; PROGNOSIS; TREATMENT OUTCOME;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPH NODE EXCISION; MALE; MIDDLE AGED; NEOPLASM STAGING; OSTEOPONTIN; PNEUMONECTOMY; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84931571161     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-014-1902-1     Document Type: Article

References (24)

1. Anborgh PH, Mutrie JC, Tuck AB, Chambers AF (2010) Role of the metastasis-promoting protein osteopontin in the tumour microenvironment. J Cell Mol Med 14(8):2037–2044
2. Bogenrieder T, Herlyn M (2003) Axis of evil: molecular mechanisms of cancer metastasis. Oncogene 22(42):6524–6536
3. Bramwell VH, Doig GS, Tuck AB, Wilson SM, Tonkin KS, Tomiak A, Perera F, Vandenberg TA, Chambers AF (2006) Serial plasma osteopontin levels have prognostic value in metastatic breast cancer. Clin Cancer Res 12(11 Pt 1):3337–3343
4. Chansky K, Sculier JP, Crowley JJ, Giroux D, Van Meerbeeck J, Goldstraw P (2009) The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol 4(7):792–801
5. Conway C, Mitra A, Jewell R, Randerson-Moor J, Lobo S, Nsengimana J, Edward S, Sanders DS, Cook M, Powell B, Boon A, Elliott F, de Kort F, Knowles MA, Bishop DT, Newton-Bishop J (2009) Gene expression profiling of paraffin-embedded primary melanoma using the DASL assay identifies increased osteopontin expression as predictive of reduced relapse-free survival. Clin Cancer Res 15(22):6939–6946
6. Coppola D, Szabo M, Boulware D, Muraca P, Alsarra M, Chambers AF, Yeatman TJ (2004) Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res 10:184–190
7. Denhardt DT, Guo X (1993) Osteopontin: a protein with diverse functions. FASEB J 7(15):1475–1482
8. Edmondson HA, Steiner PE (1954) Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 7:462–503
9. El-Tanani MK (2008) Role of osteopontin in cellular signaling and metastatic phenotype. Front Biosci 13:4276–4284
10. Hoffman PC, Mauer AM, Vokes EE (2000) Lung cancer. Lancet 355(9202):479–485
11. Hu Z, Lin D, Yuan J, Xiao T, Zhang H, Sun W, Han N, Ma Y, Di X, Gao M, Ma J, Zhang J, Cheng S, Gao Y (2005) Overexpression of osteopontin is associated with more aggressive phenotypes in human non-small cell lung cancer. Clin Cancer Res 11(13):4646–4652
12. Hui EP, Sung FL, Yu BK, Wong CS, Ma BB, Lin X, Chan A, Wong WL, Chan AT (2008) Plasma osteopontin, hypoxia, and response to radiotherapy in nasopharyngeal cancer. Clin Cancer Res 14(21):7080–7087
13. Jin Y, Tong DY, Tang LY, Chen JN, Zhou J, Feng ZY, Shao CK (2012) Expressions of osteopontin (OPN), alphanubeta3 and Pim-1 associated with poor prognosis in non-small cell lung cancer (NSCLC). Chin J Cancer Res 24(2):103–108
14. Johnston NI, Gunasekharan VK, Ravindranath A, O’Connell C, Johnston PG, El-Tanani MK (2008) Osteopontin as a target for cancer therapy. Front Biosci 13:4361–4372
15. Mack PC, Redman MW, Chansky K, Williamson SK, Farneth NC, Lara PN Jr, Franklin WA, Le QT, Crowley JJ, Gandara DR (2008) Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. J Clin Oncol 26(29):4771–4776
16. Pan HW, Ou YH, Peng SY, Liu SH, Lai PL, Lee PH, Sheu JC, Chen CL, Hsu HC (2003) Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer 98:119–127
17. Rangaswami H, Bulbule A, Kundu GC (2006) Osteopontin: role in cell signaling and cancer progression. Trends Cell Biol 16:79–87
18. Rudland PS, Platt-Higgins A, El-Tanani M, De Silva Rudland S, Barraclough R, Winstanley JH, Howitt R, West CR (2002) Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 62(12):3417–3427
19. Senger DR, Wirth DF, Hynes RO (1979) Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell 16(4):885–893
20. Siegel R, Ma J, Zou Z, Jamal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64(1):9–29
21. Sun BS, Li Y, Zhang ZF, You J, Wang CL (2013) Osteopontin combined with CD44v6, a novel prognostic biomarker in non-small cell lung cancer undergoing curative resection. Ann Thorac Surg 96:1943–1951
22. Wai PY, Kuo PC (2008) Osteopontin: regulation in tumor metastasis. Cancer Metastasis Rev 27(1):103–118
23. Weber GF (2011) The cancer biomarker osteopontin: combination with other markers. Cancer Genomics Proteomics 8(6):263–288
24. Zhang J, Takahashi K, Takahashi F, Shimizu K, Ohshita F, Kameda Y, Maeda K, Nishio K, Fukuchi Y (2001) Differential osteopontin expression in lung cancer. Cancer Lett 171(2):215–222